IL108712A0 - Pharmaceutical composition for the treatment of androgen-associated baldness comprising antisense oligomers - Google Patents

Pharmaceutical composition for the treatment of androgen-associated baldness comprising antisense oligomers

Info

Publication number
IL108712A0
IL108712A0 IL10871294A IL10871294A IL108712A0 IL 108712 A0 IL108712 A0 IL 108712A0 IL 10871294 A IL10871294 A IL 10871294A IL 10871294 A IL10871294 A IL 10871294A IL 108712 A0 IL108712 A0 IL 108712A0
Authority
IL
Israel
Prior art keywords
baldness
androgen
treatment
pharmaceutical composition
antisense oligomers
Prior art date
Application number
IL10871294A
Original Assignee
Genta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genta Inc filed Critical Genta Inc
Publication of IL108712A0 publication Critical patent/IL108712A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y103/00—Oxidoreductases acting on the CH-CH group of donors (1.3)
    • C12Y103/99—Oxidoreductases acting on the CH-CH group of donors (1.3) with other acceptors (1.3.99)
    • C12Y103/99005—3-Oxo-5alpha-steroid 4-dehydrogenase (acceptor) (1.3.99.5), i.e. steroid-5alpha-reductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C12N2310/152—Nucleic acids forming more than 2 strands, e.g. TFOs on a single-stranded target, e.g. fold-back TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
IL10871294A 1993-02-19 1994-02-20 Pharmaceutical composition for the treatment of androgen-associated baldness comprising antisense oligomers IL108712A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1954393A 1993-02-19 1993-02-19

Publications (1)

Publication Number Publication Date
IL108712A0 true IL108712A0 (en) 1994-05-30

Family

ID=21793773

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10871294A IL108712A0 (en) 1993-02-19 1994-02-20 Pharmaceutical composition for the treatment of androgen-associated baldness comprising antisense oligomers

Country Status (6)

Country Link
EP (1) EP0684764A4 (en)
JP (1) JPH08506961A (en)
AU (1) AU692148B2 (en)
CA (1) CA2156512C (en)
IL (1) IL108712A0 (en)
WO (1) WO1994018835A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2739553B1 (en) * 1995-10-06 1998-01-02 Oreal USE OF BRADYKININE ANTAGONISTS TO STIMULATE OR INDUCE HAIR GROWTH AND / OR STOP THE HAIR LOSS
US5994319A (en) * 1996-04-15 1999-11-30 Dyad Pharmaceutical Corporation Combination therapy for androgenic alopecia with antisense oligonucleotides and minoxidil
US6489163B1 (en) * 1996-05-08 2002-12-03 Board Of Regents, The University Of Texas System Ribozyme mediated inactivation of the androgen receptor
JP2002510319A (en) 1997-07-01 2002-04-02 アイシス・ファーマシューティカルス・インコーポレーテッド Compositions and methods for delivery of oligonucleotides through the gastrointestinal tract
WO1999060167A1 (en) * 1998-05-21 1999-11-25 Isis Pharmaceuticals, Inc. Compositions and methods for topical delivery of oligonucleotides
EP1469009A2 (en) * 1998-05-21 2004-10-20 Isis Parmaceuticals, Inc. Compositions and methods for non-parenteral delivery of oligonucleotides
US20020086387A1 (en) * 2000-04-13 2002-07-04 Rachel Meyers 23155 novel protein human 5-alpha reductases and uses therefor
IT1318379B1 (en) * 2000-03-08 2003-08-25 Ira Srl COSMETIC OR PHARMACEUTICAL COMPOSITION USEFUL TO INHIBIT OR DELAY HUMAN ALOPECIA THROUGH TOPICAL APPLICATION OF THE COMPOSITION.
FR2832154B1 (en) * 2001-11-09 2007-03-16 Centre Nat Rech Scient OLIGONUCLEOTIDES INHIBITORS AND THEIR USE FOR SPECIFICALLY REPRESSING A GENE
WO2005042741A2 (en) * 2003-10-21 2005-05-12 Dyad Pharmaceutical Corporation METHODS AND COMPOSITIONS FOR TREATING 5alpha-REDUCTASE TYPE 1 AND TYPE 2 DEPENDENT CONDITIONS
DE102004025881A1 (en) 2004-05-19 2006-01-05 Beiersdorf Ag Oligoribonucleotides for influencing hair growth
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
JP6768253B2 (en) * 2015-10-09 2020-10-14 井上　肇 How to get information about androgenetic alopecia in the subject
EP3497114A4 (en) * 2016-08-08 2020-04-29 Olipass Corporation Androgen receptor antisense oligonucleotides
JP7089511B2 (en) * 2016-10-11 2022-06-22 オリパス コーポレーション HIF1-α antisense oligonucleotide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021353A1 (en) * 1991-05-31 1992-12-10 Genta Incorporated Compositions and delivery systems for transdermal administration of neutral oligomers
IL107934A0 (en) * 1992-12-08 1994-04-12 Genta Inc Formation of triple helix complexes

Also Published As

Publication number Publication date
AU6243794A (en) 1994-09-14
WO1994018835A1 (en) 1994-09-01
EP0684764A1 (en) 1995-12-06
EP0684764A4 (en) 1997-10-22
AU692148B2 (en) 1998-06-04
JPH08506961A (en) 1996-07-30
CA2156512C (en) 2002-11-19
CA2156512A1 (en) 1994-09-01

Similar Documents

Publication Publication Date Title
GB9208339D0 (en) Treatment composition
GB9310241D0 (en) Cosmetic treatment of substrates
HUP9903489A3 (en) Use of epinastine for the preparation of pharmaceutical compositions treating pain
GB2264235B (en) Composition for nasal treatment
IL108712A0 (en) Pharmaceutical composition for the treatment of androgen-associated baldness comprising antisense oligomers
HUP9802861A3 (en) Use of calendula glycosides for the treatment of psoriasis
IL109280A0 (en) Neurotrophins for treatment of depression
EP0577023A3 (en) Angiotensin-ii receptor-antagonists for the treatment of arrhythmices
IL108197A0 (en) Pharmaceutical composition for preventing or treating arterioscleriosis
GB9510162D0 (en) Compositions for the treatment of skin conditions
IL105285A0 (en) Compositions for the treatment of diabetes
IL120005A0 (en) Pharmaceutical compositions for the treatment of the eye
IL105690A0 (en) Pharmaceutical compositions for the treatment of arrhythmia
KR100248098B1 (en) Pharmaceutical composition for the treatment of dementia
EP0412938A3 (en) System for the treatment of contactlenses
GB9323550D0 (en) Composition for the treatment of hydrothyroidism
ZA98584B (en) Use of stereoisomers of calendula glycosides for the treatment of psoriasis
IL119219A0 (en) Pharmaceutical compositions for treatment of the eyes
IL106961A0 (en) Pharmaceutical compositions for treatment of the eyes
GB2270260B (en) Lactide copolymers for topical treatment of the skin
IL110895A0 (en) Pharmaceutical compositions for treatment of the eyes
GB9310578D0 (en) Treatment of baldness
IL122731A0 (en) Pharmaceutical compositions for the treatment of arrhythmia
IL106917A0 (en) Compositions for the treatment of skin disorders
AUPM333594A0 (en) Pharmaceutical composition for the treatment of skin conditions